VRNA
Verona Pharma plc
- Latest sale
- $142k
- Aug 1 · No plan
- Form 4 sales
- 114
- On record
- Form 144 notices
- 6
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleNo planAug 1 2025
Sold 824 shares at $13.14 ($11k)
Brady James Aloysius, Director
No 10b5-1 planSold 3.4% of holdings ($315k position)23,176 shares leftFirst sale on recordFiling
- 2 Form 4 saleUnusualAug 1 same day
Sold 11,288 shares at $13.14 ($148k)
Austwick Michael, Director
No 10b5-1 planSold 47% of holdings ($315k position)12,712 shares leftFirst sale on recordFiling
- 3 Form 4 saleNo planAug 1 same day
Sold 1,808 shares at $13.14 ($24k)
Ackermann Christina, Director
No 10b5-1 planSold 2.7% of holdings ($866k position)64,072 shares leftFiling
- 4 Form 4 saleRoutineAug 1 same day
Sold 58,336 shares at $13.14 ($767k)
Rickard Kathleen A., Chief Medical Officer
10b5-1 planSold 2.2% of holdings ($35M position)2.6M shares left1x usual sizeFiling
- 5 Form 4 saleRoutineAug 1 same day
Sold 208,912 shares at $13.14 ($2.7M)
Hahn Mark W, Chief Financial Officer
10b5-1 planSold 1.6% of holdings ($167M position)12.5M shares left0.6x usual sizeFiling
- 6 Form 4 saleNo planAug 1 same day
Sold 9,584 shares at $13.14 ($126k)
Fisher Andrew, General Counsel
No 10b5-1 planSold 2.2% of holdings ($5.6M position)417,903 shares left0.1x usual sizeFiling
- 7 Form 4 saleNo planAug 1 same day
Sold 9,464 shares at $13.14 ($124k)
Deschamps Lisa, Director
No 10b5-1 planSold 10% of holdings ($1.2M position)84,856 shares leftFirst sale on recordFiling
- 8 Form 4 saleNo planAug 1 same day
Sold 10,808 shares at $13.14 ($142k)
Cunningham Kenneth, Director
No 10b5-1 planSold 11.9% of holdings ($1.2M position)79,776 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales, notices and lockups (120)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2025 | Cunningham Kenneth | Director | Form 4 sale | 10,808 | $142k | 11.9% | No plan | SEC |
| Aug 1, 2025 | Deschamps Lisa | Director | Form 4 sale | 9,464 | $124k | 10.0% | No plan | SEC |
| Aug 1, 2025 | Fisher Andrew | General Counsel | Form 4 sale | 9,584 | $126k | 2.2% | No plan | SEC |
| Aug 1, 2025 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 208,912 | $2.7M | 1.6% | Routine | SEC |
| Aug 1, 2025 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 58,336 | $767k | 2.2% | Routine | SEC |
| Aug 1, 2025 | Ackermann Christina | Director | Form 4 sale | 1,808 | $24k | 2.7% | No plan | SEC |
| Aug 1, 2025 | Austwick Michael | Director | Form 4 sale | 11,288 | $148k | 47.0% | Unusual | SEC |
| Aug 1, 2025 | Brady James Aloysius | Director | Form 4 sale | 824 | $11k | 3.4% | No plan | SEC |
| Aug 1, 2025 | Zaccardelli David | President and CEO | Form 4 sale | 208,912 | $2.7M | 1.5% | Routine | SEC |
| Aug 1, 2025 | Ebsworth David R | Director | Form 4 sale | 1,904 | $25k | 0.2% | No plan | SEC |
| Aug 1, 2025 | Edwards Martin | Director | Form 4 sale | 10,808 | $142k | 6.4% | No plan | SEC |
| Aug 1, 2025 | Shah Mahendra | Director | Form 4 sale | 3,608 | $47k | 3.7% | No plan | SEC |
| Aug 1, 2025 | Sinha Vikas | Director | Form 4 sale | 4,328 | $57k | 4.4% | No plan | SEC |
| Jun 16, 2025 | Fisher Andrew | General Counsel | Form 4 sale | 80,000 | $922k | 18.2% | Routine | SEC |
| Jun 11, 2025 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 400,000 | $4.6M | 3.2% | Routine | SEC |
| Jun 11, 2025 | Zaccardelli David | President and CEO | Form 4 sale | 400,000 | $4.6M | 2.9% | Routine | SEC |
| May 29, 2025 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 400,000 | $3.7M | 3.1% | Routine | SEC |
| May 29, 2025 | Zaccardelli David | President and CEO | Form 4 sale | 400,000 | $3.7M | 2.9% | Routine | SEC |
| May 20, 2025 | Sinha Vikas | Director | Form 4 sale | 160,000 | $1.5M | 68.2% | Routine | SEC |
| May 15, 2025 | Fisher Andrew | General Counsel | Form 4 sale | 80,000 | $686k | 18.2% | Routine | SEC |
| May 14, 2025 | Ackermann Christina | Director | Form 4 sale | 40,000 | $338k | 48.9% | Routine | SEC |
| May 6, 2025 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 114,984 | $1M | 4.3% | Routine | SEC |
| May 2, 2025 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 587,008 | $5.3M | 4.3% | Unusual | SEC |
| May 2, 2025 | Zaccardelli David | President and CEO | Form 4 sale | 587,008 | $5.3M | 4.0% | Unusual | SEC |
| May 1, 2025 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 49,200 | $440k | 1.8% | Routine | SEC |
| Apr 29, 2025 | Fisher Andrew | General Counsel | Form 4 sale | 26,072 | $234k | 6.8% | No plan | SEC |
| Apr 29, 2025 | Zaccardelli David | President and CEO | Form 4 sale | 90,360 | $811k | 0.6% | Routine | SEC |
| Apr 29, 2025 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 34,384 | $309k | 1.3% | Routine | SEC |
| Apr 29, 2025 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 90,360 | $811k | 0.7% | Routine | SEC |
| Apr 29, 2025 | Sinha Vikas | Director | Form 4 sale | 20,000 | $178k | 21.2% | Routine | SEC |
| Mar 12, 2025 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 79,264 | $662k | 2.9% | Routine | SEC |
| Dec 6, 2024 | Zaccardelli David | President and CEO | Form 4 sale | 870,672 | $4.4M | 5.8% | Unusual | SEC |
| Dec 6, 2024 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 881,960 | $4.4M | 6.2% | Unusual | SEC |
| Dec 2, 2024 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 113,240 | $567k | 0.8% | Routine | SEC |
| Dec 2, 2024 | Zaccardelli David | President and CEO | Form 4 sale | 125,328 | $627k | 0.8% | Routine | SEC |
| Nov 26, 2024 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 2,400 | $12k | 0.0% | Routine | SEC |
| Nov 25, 2024 | Zaccardelli David | President and CEO | Form 4 sale | 1,600 | $8k | 0.0% | Routine | SEC |
| Nov 25, 2024 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 240,000 | $1.2M | 8.2% | Routine | SEC |
| Nov 25, 2024 | Rickard Kathleen A. | Officer | Form 144 notice | 30,000 | $1.2M | Notice | SEC | |
| Nov 11, 2024 | Zaccardelli David | President and CEO | Form 4 sale | 2,400 | $12k | 0.0% | Routine | SEC |
| Nov 11, 2024 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 2,400 | $12k | 0.0% | Routine | SEC |
| Nov 4, 2024 | Zaccardelli David | President and CEO | Form 4 sale | 141,032 | $619k | 0.9% | Routine | SEC |
| Nov 4, 2024 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 129,672 | $569k | 0.9% | Routine | SEC |
| Oct 25, 2024 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 144,560 | $633k | 1.0% | Routine | SEC |
| Oct 25, 2024 | Zaccardelli David | President and CEO | Form 4 sale | 144,816 | $634k | 1.0% | Routine | SEC |
| Oct 22, 2024 | Zaccardelli David | President and CEO | Form 4 sale | 514,152 | $2.3M | 3.4% | Routine | SEC |
| Oct 22, 2024 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 525,768 | $2.3M | 3.7% | Routine | SEC |
| Sep 11, 2024 | Zaccardelli David | President and CEO | Form 4 sale | 600,000 | $2.3M | 3.8% | Routine | SEC |
| Sep 11, 2024 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 600,000 | $2.3M | 4.0% | Routine | SEC |
| Aug 13, 2024 | Zaccardelli David | President and CEO | Form 4 sale | 400,000 | $1.3M | 2.5% | Routine | SEC |
| Aug 13, 2024 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 400,000 | $1.3M | 2.6% | Routine | SEC |
| May 3, 2024 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 36,248 | $71k | 1.4% | Routine | SEC |
| Feb 5, 2024 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 36,248 | $80k | 1.3% | Routine | SEC |
| Nov 3, 2023 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 58,752 | $113k | 2.0% | Routine | SEC |
| Nov 3, 2023 | Rickard Kathleen A. | Officer | Form 144 notice | 7,344 | $110k | Notice | SEC | |
| Aug 7, 2023 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 80,144 | $203k | 2.7% | Routine | SEC |
| Aug 7, 2023 | Zaccardelli David | President and CEO | Form 4 sale | 275,888 | $694k | 1.7% | Unusual | SEC |
| Aug 7, 2023 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 275,888 | $694k | 1.7% | Routine | SEC |
| Aug 7, 2023 | Poll Claire | General Counsel | Form 4 sale | 48,472 | $122k | 2.5% | Routine | SEC |
| Aug 3, 2023 | Rickard Kathleen A. | Officer | Form 144 notice | 3,594 | $74k | Notice | SEC | |
| Aug 2, 2023 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 179,648 | $475k | 1.1% | Unusual | SEC |
| Aug 2, 2023 | Poll Claire | General Counsel | Form 4 sale | 31,552 | $83k | 1.6% | Routine | SEC |
| Aug 2, 2023 | Zaccardelli David | President and CEO | Form 4 sale | 179,648 | $475k | 1.1% | Unusual | SEC |
| Aug 2, 2023 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 33,464 | $88k | 1.1% | Routine | SEC |
| May 15, 2023 | Orbimed Advisors LLC | Director | Form 4 sale | 482,913 | $9.9M | 11.3% | No plan | SEC |
| May 15, 2023 | Gupta Rishi | Director | Form 4 sale | 482,913 | $9.9M | 11.3% | No plan | SEC |
| May 11, 2023 | Orbimed Advisors LLC | Shareholder | Form 144 notice | 2.6M | $60.4M | Notice | SEC | |
| May 3, 2023 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 106,176 | $276k | 3.5% | Unusual | SEC |
| May 3, 2023 | Rickard Kathleen A. | Officer | Form 144 notice | 3,594 | $75k | Notice | SEC | |
| May 1, 2023 | Poll Claire | General Counsel | Form 4 sale | 80,376 | $207k | 3.9% | Routine | SEC |
| May 1, 2023 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 455,528 | $1.2M | 2.8% | Unusual | SEC |
| May 1, 2023 | Zaccardelli David | President and CEO | Form 4 sale | 455,536 | $1.2M | 2.6% | Unusual | SEC |
| Mar 9, 2023 | Orbimed Capital LLC | Shareholder | Form 144 notice | 311,598 | $6.4M | Notice | SEC | |
| Feb 2, 2023 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 118,712 | $303k | 3.7% | Unusual | SEC |
| Feb 1, 2023 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 413,168 | $1.1M | 2.5% | Unusual | SEC |
| Feb 1, 2023 | Zaccardelli David | President and CEO | Form 4 sale | 432,928 | $1.1M | 2.4% | Unusual | SEC |
| Feb 1, 2023 | Poll Claire | General Counsel | Form 4 sale | 152,000 | $394k | 16.4% | Plan not stated | SEC |
| Dec 23, 2022 | OrbiMed Capital GP VI LLC | Director | Form 4 sale | 6.1M | $136M | 15.3% | Plan not stated | SEC |
| Dec 23, 2022 | Gupta Rishi | Director | Form 4 sale | 6.1M | $136M | 15.3% | Plan not stated | SEC |
| Dec 22, 2022 | Poll Claire | General Counsel | Form 4 sale | 240,000 | $646k | 23.7% | Plan not stated | SEC |
| Dec 20, 2022 | Zaccardelli David | President and CEO | Form 4 sale | 600,000 | $1.3M | 3.3% | Unusual | SEC |
| Dec 20, 2022 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 600,000 | $1.3M | 3.4% | Unusual | SEC |
| Nov 1, 2022 | Zaccardelli David | President and CEO | Form 4 sale | 32,904 | $55k | 0.2% | Plan not stated | SEC |
| Nov 1, 2022 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 28,752 | $47k | 0.9% | Plan not stated | SEC |
| Nov 1, 2022 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 13,160 | $22k | 0.1% | Plan not stated | SEC |
| Aug 9, 2022 | Zaccardelli David | President and CEO | Form 4 sale | 600,000 | $1.1M | 3.8% | Unusual | SEC |
| Aug 9, 2022 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 600,000 | $1.1M | 4.0% | Unusual | SEC |
| Aug 2, 2022 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 28,752 | $20k | 1.2% | Plan not stated | SEC |
| Aug 1, 2022 | Zaccardelli David | President and CEO | Form 4 sale | 32,904 | $23k | 0.2% | Plan not stated | SEC |
| Aug 1, 2022 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 13,168 | $9k | 0.1% | Plan not stated | SEC |
| May 3, 2022 | Zaccardelli David | President and CEO | Form 4 sale | 32,904 | $16k | 0.2% | Plan not stated | SEC |
| May 3, 2022 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 28,752 | $14k | 1.2% | Plan not stated | SEC |
| May 3, 2022 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 12,512 | $6k | 0.1% | Plan not stated | SEC |
| Apr 11, 2022 | Rickard Kathleen A. | Chief Medical Officer | Form 4 sale | 172,520 | $99k | 6.3% | Plan not stated | SEC |
| Feb 3, 2022 | Zaccardelli David | President and CEO | Form 4 sale | 52,056 | $38k | 0.3% | Plan not stated | SEC |
| Feb 2, 2022 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 10,416 | $8k | 0.1% | Plan not stated | SEC |
| Feb 1, 2022 | Deschamps Lisa | Director | Form 4 sale | 11,664 | $9k | 14.2% | Plan not stated | SEC |
| Nov 2, 2021 | Deschamps Lisa | Director | Form 4 sale | 11,672 | $8k | 12.5% | Plan not stated | SEC |
| Nov 2, 2021 | Zaccardelli David | President and CEO | Form 4 sale | 52,056 | $33k | 0.3% | Plan not stated | SEC |
| Nov 2, 2021 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 10,416 | $7k | 0.1% | Plan not stated | SEC |
| Aug 4, 2021 | Zaccardelli David | President and CEO | Form 4 sale | 34,400 | $26k | 0.2% | Plan not stated | SEC |
| Aug 3, 2021 | Zaccardelli David | President and CEO | Form 4 sale | 17,656 | $13k | 0.1% | Plan not stated | SEC |
| Aug 2, 2021 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 10,416 | $8k | 0.1% | Plan not stated | SEC |
| May 4, 2021 | Ullman Anders | Director | Form 4 sale | 12,056 | $10k | 3.5% | Plan not stated | SEC |
| May 4, 2021 | Deschamps Lisa | Director | Form 4 sale | 10,680 | $9k | 9.2% | Plan not stated | SEC |
| May 4, 2021 | Cunningham Kenneth | Director | Form 4 sale | 13,112 | $11k | 16.5% | Plan not stated | SEC |
| May 4, 2021 | Sinha Vikas | Director | Form 4 sale | 10,016 | $8k | 11.9% | Plan not stated | SEC |
| May 4, 2021 | Ebsworth David R | Director | Form 4 sale | 11,184 | $9k | 1.6% | Plan not stated | SEC |
| May 4, 2021 | Edwards Martin | Director | Form 4 sale | 12,024 | $10k | 9.8% | Plan not stated | SEC |
| May 4, 2021 | Shah Mahendra | Director | Form 4 sale | 10,680 | $9k | 12.8% | Plan not stated | SEC |
| May 4, 2021 | Zaccardelli David | President and CEO | Form 4 sale | 52,056 | $42k | 0.3% | Plan not stated | SEC |
| May 3, 2021 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 10,416 | $9k | 0.1% | Plan not stated | SEC |
| Mar 1, 2021 | Hahn Mark W | Chief Financial Officer | Form 4 sale | 26,728 | $30k | 0.1% | Plan not stated | SEC |
| Mar 1, 2021 | Zaccardelli David | President and CEO | Form 4 sale | 43,392 | $49k | 0.2% | Plan not stated | SEC |
| Feb 1, 2021 | Ullman Anders | Director | Form 4 sale | 10,800 | $11k | 3.0% | Plan not stated | SEC |
| Feb 1, 2021 | Sinha Vikas | Director | Form 4 sale | 10,224 | $10k | 10.8% | Plan not stated | SEC |
| Feb 1, 2021 | Shah Mahendra | Director | Form 4 sale | 10,800 | $11k | 11.4% | Plan not stated | SEC |
| Feb 1, 2021 | Edwards Martin | Director | Form 4 sale | 13,688 | $14k | 10.0% | Plan not stated | SEC |
| Feb 1, 2021 | Ebsworth David R | Director | Form 4 sale | 11,912 | $12k | 1.7% | Plan not stated | SEC |
| Feb 1, 2021 | Cunningham Kenneth | Director | Form 4 sale | 13,104 | $13k | 14.1% | Plan not stated | SEC |